FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	20549
vvasi ii iytori,	D.C.	20349

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Rhodes Jason P					2. Issuer Name and Ticker or Trading Symbol Gemini Therapeutics, Inc. /DE [GMTX]								ck all applic	able)	g Pers	son(s) to Iss				
(Last) (First) (Middle) 300 TECHNOLOGY SQ., 8TH FLOOR					3. Date of Earliest Transaction (Month/Day/Year) 10/04/2021								Officer below)	(give title		Other (s below)	pecify			
(Street) CAMBR (City)			02139 (Zip)		4. If								6. Ind Line)	Form fi	vidual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					Execution Date,			3. Transaction Code (Instr. 3, 4) 5) 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4)			4 and Securitie Beneficia		es Form ally (D) of Following (I) (Ir		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
								Code	/	Amount	(A) or (D)	Pı	rice	Transact (Instr. 3 a	tion(s)			,msu. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Cc	Transaction Code (Instr.				6. Date Exercisab Expiration Date (Month/Day/Year)		of Securities		ies g Secu		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transaction (Instr. 4)	i ily	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership ct (Instr. 4)	
					ode	v	(A)	(D)	Date Exercisable		xpiration ate	Title	or	ount mber ares						
Stock Option (Right to Buy)	\$3.8	10/04/2021			A		17,245		(1)	10	0/03/2031	Common Stock	17,	245	\$0.00	17,24	5	D ⁽²⁾		

Explanation of Responses:

1. This option shall vest and become exercisable on the earlier of (a) the one (1)-year anniversary of the Grant Date and (b) the Company's next annual meeting of stockholders, in each case, so long as the Optionee continues to have a Service Relationship with the Company on such date.

Remarks:

<u>/s/ Jason Meyenburg, attorney-in-fact</u> 10/06/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{2.} This option was granted to the Reporting Person, a director of the Issuer and a member of Atlas Venture Life Science Advisors, LLC ("Atlas"). The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.